7月30日周三盘中，港股上市公司维立志博-B（09887）股价出现显著上涨，截至上午9时52分，该股涨幅达到5.01%。维立志博-B是一家专注于创新药物研发的生物科技公司，其核心产品管线包括备受市场关注的4-1BB双抗药物。
回顾维立志博-B的近期表现，该公司上市首日就实现了92%的巨幅涨幅，吸引了超过3000亿港元的资金认购，充分体现了市场对4-1BB双抗技术的热情。公司目前的总市值已达到18亿美元，成为生物科技领域的新星。
分析人士认为，维立志博-B今日的股价上涨可能与市场对4-1BB双抗药物持续看好有关。随着更多投资者认识到这一创新疗法的潜力，以及公司在该领域的领先地位，维立志博-B的股价可能会继续受到追捧。此外，生物科技行业整体向好的氛围也可能是推动该股上涨的因素之一。投资者应密切关注公司未来的研发进展和临床数据，这些都可能成为影响股价的关键因素。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.